A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 1000 participants.

Also called NCT03683186

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03683186
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Portugal, Romania, Serbia, Singapore, South Korea, Spain, Sweden, Taiwan, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT03683186. Allocation not applicable; no masking; primary purpose treatment. Start 2019-09-23 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Condition
PAH
Condition
Pulmonary Arterial Hypertension
Condition
Hypertension
Condition
Connective Tissue Diseases
Condition
Familial Primary Pulmonary Hypertension
Condition
Vascular Diseases
Condition
Cardiovascular Diseases
Condition
Hypertension, Pulmonary
Condition
Lung Diseases
Condition
Respiratory Tract Disease
Intervention (Drug)
Ralinepag
Lead sponsor
United Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct03683186
Content hash
794df791e0628041ff56082641067824af5c4d96cc7e2ac9c5bd44e5c3c7bd85